Albert Chiou, MD
Dermatology · Stanford, CANPI 1609119783
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,600 of the $11,270 with a category attached, or 94.1%. Pfizer accounts for 83.2% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2021 at $4,950 and has fallen 74.7% since, to $1,250 in 2024.
Across 8 payments — averaging $1408.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$9K
- Sanofi$1K
- AbbVie$515
- Novartis$125
Across 221 payments — averaging $4112.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$606K
- Sanofi$279K
- Regeneron$14K
- Novartis$5K
- Sanofi US Services Inc.$4K
What the payments were for
- Consulting fees$5004%
- Speaking & faculty fees$10,60094%
- Food & beverage$1251%
- Education$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,270 in reported general payments places this provider in the 80th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx Sensoready (2 Pens)Secukinumab | 16 | $130,893 |
| Dupixent SyringeDupilumab | 20 | $77,410 |
| Tacrolimus | 16 | $2,954 |
| Clobetasol Propionate | 34 | $1,540 |
| Ketoconazole | 91 | $1,522 |
| Fluocinonide | 32 | $1,080 |
| Metronidazole | 30 | $1,038 |
| Sulfacetamide Sodium | 11 | $709 |
| Triamcinolone Acetonide | 55 | $674 |
| Clindamycin Phosphate | 24 | $440 |
| ValacyclovirValacyclovir Hcl | 11 | $270 |
| Mupirocin | 16 | $166 |
| Hydrocortisone | 33 | $159 |
| Finasteride | 14 | $63 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Stanford
- Matthew LewisStanford$442K
- Justin KoStanford$237K
- David FiorentinoStanford$166K
- Paul YamauchiSanta Monica$2.9M
- Jennifer SoungSanta Ana$2.8M
- Robert GreenbergLivermore$2.6M
- Neal BhatiaSan Diego$2.5M
- April ArmstrongLos Angeles$2.3M
- Jeffrey CrowleyBakersfield$2.1M
- Jashin WuCorona$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.